Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2 in China: A case-control study DOI Open Access
Xiaqing Zhang, Yao Wang, Cheng‐Yang Hu

и другие.

Authorea (Authorea), Год журнала: 2022, Номер unknown

Опубликована: Дек. 30, 2022

ABSTRACT Background: Real-world evidence on the effectiveness of COVID-19 vaccines marketed in China against Omicron BA.2 variant remains scarce. Methods: A case-control study was conducted to estimate vaccine (VE) China, including inactivated vaccines, an Ad5-nCoV vaccine, and a recombinant protein vaccine. The included 414 participants infected with SARS-CoV-2 as cases 828 individuals close contact patients controls during outbreak April 2022 Lu’an City, Anhui Province, China. Controls were selected from core contacts based random sampling method consecutive negative test results. Each case corresponded two controls. Results: total this study. Compared unvaccinated participants, overall VE infection vaccinated group any 35.0% (95% CI: −9.1–61.3%), whereas for booster vaccination 51.6% 15.2–72.4%). Subgroup analysis showed that (65.8%, 95% 12.8–86.6%) higher than (35.5%, 95%CI:-8.6–61.7%) (13.0%, 95%CI:-76.1–57%). offered 46.8% 9.5–68.7%) protection within 6 months, no after months. heterologous (76.4%, 14.3–93.5%) considerably homologous (51.8%, 9.6–74.3%). Conclusion: Booster more full vaccination. campaign dose three doses must be urgently conducted. Keywords vaccines; Omicron; effectiveness; vaccine;

Язык: Английский

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2 in China: A case-control study DOI Open Access
Xiaqing Zhang, Yao Wang, Cheng‐Yang Hu

и другие.

Authorea (Authorea), Год журнала: 2022, Номер unknown

Опубликована: Дек. 30, 2022

ABSTRACT Background: Real-world evidence on the effectiveness of COVID-19 vaccines marketed in China against Omicron BA.2 variant remains scarce. Methods: A case-control study was conducted to estimate vaccine (VE) China, including inactivated vaccines, an Ad5-nCoV vaccine, and a recombinant protein vaccine. The included 414 participants infected with SARS-CoV-2 as cases 828 individuals close contact patients controls during outbreak April 2022 Lu’an City, Anhui Province, China. Controls were selected from core contacts based random sampling method consecutive negative test results. Each case corresponded two controls. Results: total this study. Compared unvaccinated participants, overall VE infection vaccinated group any 35.0% (95% CI: −9.1–61.3%), whereas for booster vaccination 51.6% 15.2–72.4%). Subgroup analysis showed that (65.8%, 95% 12.8–86.6%) higher than (35.5%, 95%CI:-8.6–61.7%) (13.0%, 95%CI:-76.1–57%). offered 46.8% 9.5–68.7%) protection within 6 months, no after months. heterologous (76.4%, 14.3–93.5%) considerably homologous (51.8%, 9.6–74.3%). Conclusion: Booster more full vaccination. campaign dose three doses must be urgently conducted. Keywords vaccines; Omicron; effectiveness; vaccine;

Язык: Английский

Процитировано

0